AMRX logo

AMNEAL PHARMACEUTICALS INC

AMRXNASDAQ
πŸ† #1120 by market capEarnings Oct 29US Equity
$20.20β–Ό $0.29 (βˆ’1.46%)
Market closed Β· at close
πŸ””
Track AMRX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.5%
7dβ–² 4.4%
14dβ–² 11.7%
30dβ–² 15.6%
ytdβ–² 60.4%
1yβ–² 101.6%
🏦Market Cap
$6.45B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+8.1%
Slowing
πŸ“ŠGross Margin
39.3%
Healthy
πŸ’΅FCF Margin
2.7%
Thin
βš–οΈP/S Ratio
2.1x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$20.12 – $20.38
52-Week Range
$9.56 – $21.18
Volume
$2.24B
Avg Volume
$2.37B
Shares Outstanding
319.3M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$3.02B
Last Q Revenue
$796M
P/E Ratio
41.2
P/S Ratio
2.1x
EPS (TTM)
$0.49
Dividend Yield
0.00%
Dilution (1yr)
+4.8%

Why Investors Own AMRX

  • βœ“High-growth profile β€” revenue up +5.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 51% gross margin and 13% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AMRX logo

AMNEAL PHARMACEUTICALS INC

AMRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3.0Bβ–² +8.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
37.6%β–² +3.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$423Mβ–² +69.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$270Mβ–² +22.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
324.8Mβ–² +4.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.4Bβ–² +$57M YoY
StockOtter Β· stockotter.space

About AMNEAL PHARMACEUTICALS INC

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy3
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

GuruFocusΒ·1d ago

A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- GF Value $8.19 vs Price $20.50

On September 28, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 3.7% to $20.50, reflecting strong price performance especially in the context of its 52-wee

GlobeNewsWireΒ·11d ago

Amneal Announces FDA Approval and Launch of Lanreotide Injection

- Expands complex injectables portfolio with important long-acting oncology treatmentΒ - Immediate commercial launch supported by in-house production

Zacks Investment ResearchΒ·12d ago

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

GuruFocusΒ·14d ago

Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Overvalued -- GF Score: 59/100

On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat

Zacks Investment ResearchΒ·Aug 27

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.

Zacks Investment ResearchΒ·Aug 20

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.